Bullous Dermatosis in an End-Stage Renal Disease Patient: A Case Report and Literature Review

Bhat, Zeenat; Minshar, Marwan Abu; Imran, Nashat; Thompson, Andrew; Malik, Yahya Osman

doi:10.1155/2016/6713807

Cited by 4 publications

(5 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, specific studies on the use of dapsone in patients with concurrent ESKD and pemphigoid diseases are limited. This kind of treatment was reported in eight cases and benefited four patients with an average reported dose of 62.5 mg/day ( 20 , 72 , 74 , 75 ). Adverse effects including epigastric pain and mild hypertension were reported ( 73 ).…”

Section: Resultsmentioning

confidence: 99%

Pemphigoid diseases in patients with end-stage kidney diseases: pathogenesis and treatment

Yang,

Wang,

Zuo

2024

Front. Immunol.

View full text Add to dashboard Cite

BackgroundPemphigoid diseases constitute a group of autoimmune blistering disorders characterized by subepithelial blistering. The association between pemphigoid diseases and both end-stage kidney disease (ESKD) and its treatment is notable. However, there is limited evidence about the management of pemphigoid diseases in patients with ESKD. This systematic review compiled case reports and relevant studies, summarized the underlying mechanisms of pemphigoid diseases in patients with ESKD, and summarized the efficacy of various therapies.MethodsA systematic search of PubMed and Embase was performed for articles published between 1982 to June 2, 2024.ResultsFifty-three case reports and eight relevant studies were included. Triggers for pemphigoids in patients with ESKD included materials used to treat ESKD, immune dysregulation of patients with ESKD, and rejection of renal allograft. Treatment for these patients included removing triggers, as well as administering of corticosteroids, mycophenolate mofetil (MMF), tetracyclines, rituximab, methotrexate, dapsone, azathioprine, cyclosporine, intravenous immunoglobin (IVIG), plasmapheresis, and Janus kinase inhibitors.ConclusionRemoving triggers is the most effective strategy. Despite their suboptimal efficacy, corticosteroids remain the most commonly used agents in this patient population. MMF, tetracyclines, and rituximab are less used but with benefits. There are significant adverse effects associated with methotrexate treatment. Other treatment may also be beneficial and require further investigation. These findings may enable clinicians to optimize the therapeutic approach for these patients.

show abstract

Section: Resultsmentioning

confidence: 99%

Pemphigoid diseases in patients with end-stage kidney diseases: pathogenesis and treatment

Yang,

Wang,

Zuo

2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…The clinical course. BPDAI: bullous pemphigoid disease area index therefore, it was necessary to carefully differentiate the diagnosis when we observed bullous dermatosis (10). Although there are limited data on the incidence of BP in ESKD patients, one single-center 10-year study showed that the incidence of BP in peritoneal dialysis patients was 3/478.3 person-years (7).…”

Section: Discussionmentioning

confidence: 99%

“…Although there are limited data on the incidence of BP in ESKD patients, one single-center 10-year study showed that the incidence of BP in peritoneal dialysis patients was 3/478.3 person-years (7). As a rare autoimmune dermopathy, IgArelated diseases, such as linear IgA dermatosis and dermatitis herpetiformis, have been reported in ESKD patients, being characterized by subepidermal vesicles with IgA deposition in the dermal papillae and BMZ (10).…”

Section: Discussionmentioning

confidence: 99%

Bullous Pemphigoid in X-linked Alport Syndrome

et al. 2023

View full text Add to dashboard Cite

Skin lesions in X-linked Alport syndrome (XLAS) are rarely observed. Bullous pemphigoid (BP) is caused by autoantibodies against BP180, also called α1 (XVII) chain, in the basement membrane zone (BMZ). A 48-year-old man with XLAS developed tense blisters. A skin biopsy showed a cleft between the basal cell layer and dermis, with the infiltration of neutrophils and eosinophils. α1 (XVII) staining was positive on the epidermal side of α2/5 (IV) staining. Oral prednisolone improved his symptoms gradually. Abundant tense blisters on the palms and soles might suggest an important role of the α5 (IV) chain in the integrity of BMZ.

show abstract

“…The study also found that xerosis could be linked to anuria [5] The prevalence of xerosis in ESRD patients has been reported significantly in the above studies and is about 63% to 96%. [5][6][7][8][9][10][11][12]Various ways to control this disorder have been suggested, one of which is to reduce the duration of skin-to-skin contact with water. It has also been suggested to use superficial skin moisturizers in these patients.…”

Section: Superficial Skin Infection That Can Be Bacterial Fungal or Viralmentioning

confidence: 99%

Common mucocutaneous manifestations of patients with End Stage Renal Disease: A comprehensive review study

Mirahmadi¹,

Anaraki²,

Goodarzi³

2021

PJMHS

View full text Add to dashboard Cite

One of the notable points in ESRD patients is the multiplicity of skin manifestations which can include a wide range. It can also affect the living standards of patients due to its many types and severity. Careful study, as well as intense follow-up of these manifestations, can help physicians in timely diagnosis and their control or treatment. In this study, we tried to study the common mucocutaneous manifestations that occur in these patients. All references can be searched from PubMed. Sources of this study have been studied for clinical manifestations, pathophysiology, and treatment of skin manifestations in ESRD patients. In this study, xerosis, pruritus, pigmentation disorders, half and half nails, perforating disorder, and skin infections as well as appendageal disorders (hair and nail) in ESRD patients have been studied. These can be associated with other diseases and increase by disease severity. For better results and more help to patients with this disease, it seems that more and more comprehensive studies are needed. Key words: End stage renal disease, ESRD, mucucutaneous, skin, dermatology, xerosis, pigmentation disorders, infection, perforating disorder, half and half nails

show abstract

Bullous Dermatosis in an End-Stage Renal Disease Patient: A Case Report and Literature Review

Cited by 4 publications

References 23 publications

Pemphigoid diseases in patients with end-stage kidney diseases: pathogenesis and treatment

Pemphigoid diseases in patients with end-stage kidney diseases: pathogenesis and treatment

Bullous Pemphigoid in X-linked Alport Syndrome

Common mucocutaneous manifestations of patients with End Stage Renal Disease: A comprehensive review study

Contact Info

Product

Resources

About